Loading...
•
Jul 01, 2022
Envista Q2 2022 Earnings Report
Reported a solid quarter with core sales growth and progress in transforming the portfolio through acquisitions.
Key Takeaways
Envista Holdings Corporation announced Q2 2022 results with sales increasing 1.3% to $645.8 million and core sales growth of 4.0%. Net income was $44.5 million, or $0.25 per diluted share, while adjusted net income was $86.0 million, or $0.48 per diluted share. The company closed acquisitions of Carestream Dental’s Intraoral Scanner Business and Osteogenics' Regenerative Solutions business.
Delivered core sales growth of 4% and adjusted EBITDA margins of 19.7%.
Navigated challenging operating environment with supply chain disruptions and inflation.
Closed acquisitions of Carestream Dental’s Intraoral Scanner Business and Osteogenics' Regenerative Solutions business.
Updated 2022 guidance to mid-single digits core sales growth, committed to 20% adjusted EBITDA margin.
Revenue by Segment
Forward Guidance
Given the persistent inflationary pressures, continued supply chain disruptions, and an uncertain geopolitical environment, Envista is updating its guidance for 2022 and now expects core sales to grow mid-single digits for 2022. They remain committed to delivering an adjusted EBITDA margin of 20% for the full year.
Challenges Ahead
- Persistent inflationary pressures
- Continued supply chain disruptions
- Uncertain geopolitical environment
- Additional downside risk for demand in the second half of 2022
- Certain information is not available and cannot be reasonably estimated on a GAAP basis
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...